Imaging Diagnostic Systems, Inc. (OTCBB:IMDS), a pioneer in laser optical breast imaging systems, exhibited CT Laser Mammography (CTLM®) clinical results at the annual European Congress of Radiology (ECR 2009), March 6-10, in Vienna, Austria. IDSI is located at Expo 574.

The clinical study accepted as one of the conferences' presentations was from the Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. The study demonstrated that: "when the CTLM system was used as an adjunct to mammography in heterogeneously and extremely dense breasts, the sensitivity (detecting cancer) increased significantly." See company website for details of the published clinical report.

One of the largest medical meetings in Europe and the second-largest radiology meeting in the world, ECR 2009 is expected to attract an estimated 18,000 participants worldwide.

About Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

The company is currently undergoing the clinical studies required for the Premarket approval application. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States.

For more information, visit our website: http://www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Imaging Diagnostic Systems, Inc